Citation Impact
Citing Papers
Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
2011
Ten things you should know about protein kinases: IUPHAR R eview 14
2015
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
2011
Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2012
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
2010
Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro
2017
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
2010
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
fastp: an ultra-fast all-in-one FASTQ preprocessor
2018 Standout
Cancer statistics, 2022
2022 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Degradation of proteins by PROTACs and other strategies
2019
Advances in targeted degradation of endogenous proteins
2019
Cancer Statistics, 2021
2021 Standout
Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
2020
Structure of the TRPA1 ion channel suggests regulatory mechanisms
2015 StandoutNatureNobel
Mechanisms, regulation and functions of the unfolded protein response
2020 Standout
A view on drug resistance in cancer
2019 StandoutNature
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Hepatocellular carcinoma
2016 Standout
Liquid biopsy: monitoring cancer-genetics in the blood
2013
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Targeting Nuclear Receptors with PROTAC degraders
2019
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
2013
Integrating liquid biopsies into the management of cancer
2017
The Evolving War on Cancer
2011
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
2017
Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase
2016
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Clinical and therapeutic relevance of cancer-associated fibroblasts
2021
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
2018
Hepatocellular carcinoma
2021 Standout
The Emerging Role of “Liquid Biopsies,” Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations
2017
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Targeted covalent drugs of the kinase family
2010
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Lung cancer: current therapies and new targeted treatments
2016 Standout
CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations
2016
The hypoxic tumor microenvironment: A driving force for breast cancer progression
2015 StandoutNobel
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
2014
Implementing Genome-Driven Oncology
2017
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Emerging Role of mTOR in the Response to Cancer Therapeutics
2016
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
EMT: 2016
2016 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
2014 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
A fate worse than death: apoptosis as an oncogenic process
2016
Applications of machine learning in drug discovery and development
2019 Standout
Integrated digital error suppression for improved detection of circulating tumor DNA
2016
The molecular landscape of head and neck cancer
2018 Standout
Mitochondria as multifaceted regulators of cell death
2019 Standout
Efficient generation of mouse models of human diseases via ABE- and BE-mediated base editing
2018 Standout
Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities
2021
The PI3K Pathway in Human Disease
2017 Standout
Acquired resistance to TKIs in solid tumours: learning from lung cancer
2014
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
2016
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
NCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics Signatures
2014
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
2015
A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA
2011
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Induced protein degradation: an emerging drug discovery paradigm
2016
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
2019
Vesicle Trafficking and RNA Transfer Add Complexity and Connectivity to Cell–Cell Communication
2013
Targeted Covalent Inhibitors for Drug Design
2016
Genetic Landscape of Human Papillomavirus–Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors
2015
Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
2016
Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment
2013
Oligosaccharyltransferase: A Gatekeeper of Health and Tumor Progression
2019
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
2016
Redox regulation of tyrosine kinase signalling: more than meets the eye
2019
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
2012
Cysteine-Mediated Redox Signaling: Chemistry, Biology, and Tools for Discovery
2013
Cancer Genome Landscapes
2013 StandoutScience
A Heck–Matsuda Process for the Synthesis of β‐Arylethenesulfonyl Fluorides: Selectively Addressable Bis‐electrophiles for SuFEx Click Chemistry
2016 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
2014
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
2017
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
2019
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Works of Dalia Ercan being referenced
Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
2014
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer
2015
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
2012
Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET
2012
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
2015
Pharmacological targeting of the pseudokinase Her3
2014
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
2017
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
2010
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
2015
Discovery of selective irreversible inhibitors for EGFR-T790M
2010
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
2015
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines
2014
Abstract 4832: Novel EGFR mutations that cause drug resistance to irreversible pyrimidine but not quinazoline based EGFR inhibitors
2012